The U.S. Food and Drug Administration (FDA) has granted marketing clearance to AMLD, an bio-pharmaceutical company, for their device, DR-70, to detect for recurrences or progression of disease among patients diagnosed with colorectal cancer.
DR-70 is an enzyme-linked immunosorbent assay that monitors for progression or recurrence of colorectal cancer through quantification of fibrin degradation found in the bloodstream as products shed by malignant cells.
Marketing clearance of DR-70 is the first clearance granted by the FDA for monitoring colorectal cancer since January 1982.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
